BCSC-1 suppresses human breast cancer metastasis by inhibiting NF-κB signaling

Di,Dalin; Chen,Lei; Guo,Yingying; Wang,Lina; Zhao,Chunling; Ju,Jiyu

doi:10.3892/ijo.2018.4309

BCSC-1 suppresses human breast cancer metastasis by inhibiting NF-κB signaling

Authors:
- Dalin Di
- Lei Chen
- Yingying Guo
- Lina Wang
- Chunling Zhao
- Jiyu Ju
View Affiliations

Affiliations: Department of Immunology, Weifang Medical University, Weifang, Shandong 261053, P.R. China, Department of Hematology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, School of Biological Science, Weifang Medical University, Weifang, Shandong 261053, P.R. China
Published online on: March 7, 2018 https://doi.org/10.3892/ijo.2018.4309
Pages: 1674-1684

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer suppressor candidate-1 (BCSC-1; also termed von Willebrand factor A domain containing 5A and LOH11CR2A) is a newly identified candidate tumor suppressor gene that has been implicated in several types of cancer in previous studies. However, there have been few reports about the association between BCSC-1 and human breast cancer in recent years. In the present study, the expression of BCSC-1 in breast cancer was determined by immunohistochemistry (IHC) staining of tissue microarrays and clinical tissue specimens. Subsequently, BCSC-1 gene expression was evaluated in different breast cancer cell lines by quantitative polymerase chain reaction and the MDA-MB-231 cell line was selected for further use in subsequent experiments, due to its low BCSC-1 expression. An MDA-MB-231 cell line with stable overexpression of BCSC-1 was established through transfection with plasmid containing the BCSC-1 gene, and then screening for G418 resistance. Wound-healing, migration and invasion assays were conducted to detect the effect of BCSC-1 on MDA-MB-231 cells. Furthermore, changes in matrix metalloproteinases (MMPs), osteopontin (OPN) and the nuclear factor-κB (NF-κB) pathway were detected in the current study. Additionally, stable silencing of BCSC-1 expression in MCF-7 cells was performed using a lentivirus. The results of IHC indicated that BCSC-1 is expressed at low levels in breast cancer tissues compared with in normal breast tissue. Results of the wound healing, migration and invasion assays demonstrated that BCSC-1 overexpression reduced the metastasis ability of MDA-MB-231 cells in vitro. Further research confirmed that the BCSC-1 overexpression reduced the expression levels of MMP7, MMP9 and OPN, and the phosphorylation of NF-κB p65. Furthermore, inhibition of BCSC-1 via lentivirus-mediated RNA interference revealed that the downregulation of BCSC-1 increased the invasive ability of MCF-7 cells. In summary, the results demonstrated that BCSC-1 is expressed at low levels in breast cancer tissues, and that it can suppress human breast cancer cell migration and invasion, potentially altering the expression of MMP7, MMP9, OPN, and the activity of the NF-κB pathway. Therefore, BCSC-1 may be useful as a biomarker for the treatment of breast cancer in the future.

View Figures

View References

1	Hong W and Dong E: The past, present and future of breast cancer research in China. Cancer Lett. 351:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
2	Organization WH: Breast cancer: Prevention and control. World Health Stat Annu. 41:697–700. 2012.
3	Müller V, Fuxius S, Steffens CC, Lerchenmüller C, Luhn B, Vehling-Kaiser U, Hurst U, Hahn LJ, Soeling U, Wohlfarth T, et al: Quality of life under capecitabine (Xeloda^®) in patients with metastatic breast cancer: Data from a german non-interventional surveillance study. Oncol Res Treat. 37:748–755. 2014. View Article : Google Scholar
4	Lu J and Jin ML: Short-hairpin RNA-mediated MTA2 silencing inhibits human breast cancer cell line MDA-MB231 proliferation and metastasis. Asian Pac J Cancer Prev. 15:5577–5582. 2014. View Article : Google Scholar : PubMed/NCBI
5	Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA and Ramesh R: Tumor suppressor gene-based nanotherapy: From test tube to the clinic. J Drug Deliv. 2011:4658452011. View Article : Google Scholar : PubMed/NCBI
6	Martin ES, Cesari R, Pentimalli F, Yoder K, Fishel R, Himelstein AL, Martin SE, Godwin AK, Negrini M and Croce CM: The BCSC-1 locus at chromosome 11q23–q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci USA. 100:11517–11522. 2003. View Article : Google Scholar
7	Zhao CL, Yu WJ, Gao ZQ, Li WT, Gao W, Yang WW, Feng WG and Ju JY: Association of BCSC-1 with human esophageal squamous cell carcinoma. Neoplasma. 62:765–769. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zhou YQ, Chen SL, Ju JY, Shen L, Liu Y, Zhen S, Lv N, He ZG and Zhu LP: Tumor suppressor function of BCSC-1 in nasopharyngeal carcinoma. Cancer Sci. 100:1817–1822. 2009. View Article : Google Scholar : PubMed/NCBI
9	Anghel SI, Correa-Rocha R, Budinska E, Boligan KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, et al: Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF. Pigment Cell Melanoma Res. 25:482–487. 2012. View Article : Google Scholar : PubMed/NCBI
10	Mali AV, Wagh UV, Hegde MV, Chandorkar SS, Surve SV and Patole MV: In vitro anti-metastatic activity of enterolactone, a mammalian lignan derived from flax lignan, and down-regulation of matrix metalloproteinases in MCF-7 and MDA MB 231 cell lines. Indian J Cancer. 49:181–187. 2012. View Article : Google Scholar : PubMed/NCBI
11	Tong W, Wang Q, Sun D and Suo J: Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9. Oncol Lett. 12:4139–4146. 2016. View Article : Google Scholar : PubMed/NCBI
12	Hao C, Cui Y, Hu MU, Zhi X, Zhang L, Li W, Wu W, Cheng S and Jiang WG: OPN-a splicing variant expression in non-small cell lung cancer and its effects on the bone metastatic abilities of lung cancer cells in vitro. Anticancer Res. 37:2245–2254. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ishigamori R, Komiya M, Takasu S, Mutoh M, Imai T and Takahashi M: Osteopontin deficiency suppresses intestinal tumor development in Apc-deficient min mice. Int J Mol Sci. 18:182017. View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Xu YM, Wang HJ, Chen F, Guo WH, Wang YY, Li HY, Tang JH, Ding Y, Shen YC, Li M, et al: HRD1 suppresses the growth and metastasis of breast cancer cells by promoting IGF-1R degradation. Oncotarget. 6:42854–42867. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ding F, Wang J, Zhu G, Zhao H, Wu G and Chen L: Osteopontin stimulates matrix metalloproteinase expression through the nuclear factor-κB signaling pathway in rat temporomandibular joint and condylar chondrocytes. Am J Transl Res. 9:316–329. 2017.
17	Ahn KS and Aggarwal BB: Transcription factor NF-kappaB: A sensor for smoke and stress signals. Ann NY Acad Sci. 1056:218–233. 2005. View Article : Google Scholar
18	Shishodia S and Aggarwal BB: Nuclear factor-kappaB activation: A question of life or death. J Biochem Mol Biol. 35:28–40. 2002.
19	Lin A and Karin M: NF-kappaB in cancer: A marked target. Semin Cancer Biol. 13:107–114. 2003. View Article : Google Scholar : PubMed/NCBI
20	Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, Takaoka M, Murata T, Nobuhisa T, Yamatsuji T, et al: Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res. 289:27–35. 2003. View Article : Google Scholar : PubMed/NCBI
21	Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB and Wistuba II: Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 107:2637–2646. 2006. View Article : Google Scholar
22	Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J, Zhi X and Zhang J: Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis. 6:e20202015. View Article : Google Scholar : PubMed/NCBI
23	Bharti AC and Aggarwal BB: Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol. 64:883–888. 2002. View Article : Google Scholar : PubMed/NCBI
24	Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S and Aggarwal BB: Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol. 169:6490–6497. 2002. View Article : Google Scholar
25	Sethi G, Sung B and Aggarwal BB: Nuclear factor-kappaB activation: From bench to bedside. Exp Biol Med (Maywood). 233:21–31. 2008. View Article : Google Scholar
26	Ahn KS, Sethi G and Aggarwal BB: Nuclear factor-kappa B: From clone to clinic. Curr Mol Med. 7:619–637. 2007. View Article : Google Scholar : PubMed/NCBI
27	Lee CH, Jeon YT, Kim SH and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 29:19–35. 2007. View Article : Google Scholar : PubMed/NCBI
28	Abbas A, Aukrust P, Russell D, Krohg-Sørensen K, Almås T, Bundgaard D, Bjerkeli V, Sagen EL, Michelsen AE, Dahl TB, et al: Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis. PLoS One. 9:e849352014. View Article : Google Scholar : PubMed/NCBI
29	Cuadriello EF, Fernández-Guinea Ó, Eiró N, González LO, Junquera S and Vizoso FJ: Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and tumor expression of metalloproteases and their inhibitors in invasive breast cancer. Magn Reson Imaging. 34:1107–1113. 2016. View Article : Google Scholar : PubMed/NCBI
30	Makhoul I, Todorova VK, Siegel ER, Erickson SW, Dhakal I, Raj VR, Lee JY, Orloff MS, Griffin RJ, Henry-Tillman RS, et al: Germline genetic variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA are associated with pathologic complete response to bevacizumab in breast cancer patients. PLoS One. 12:e01685502017. View Article : Google Scholar : PubMed/NCBI
31	Liu D, Guo H, Li Y, Xu X, Yang K and Bai Y: Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: A meta-analysis. PLoS One. 7:e312512012. View Article : Google Scholar : PubMed/NCBI
32	Xiao C, Wu CH and Hu HZ: LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 20:2819–2824. 2016.PubMed/NCBI
33	Beeghly-Fadiel A, Shu XO, Long J, Li C, Cai Q, Cai H, Gao YT and Zheng W: Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int J Cancer. 124:208–214. 2009. View Article : Google Scholar :
34	Mon NN, Senga T and Ito S: Interleukin-1β activates focal adhesion kinase and Src to induce matrix metalloproteinase-9 production and invasion of MCF-7 breast cancer cells. Oncol Lett. 13:955–960. 2017. View Article : Google Scholar : PubMed/NCBI
35	Hwang JK, Yu HN, Noh EM, Kim JM, Hong OY, Youn HJ, Jung SH, Kwon KB, Kim JS and Lee YR: DHA blocks TPA-induced cell invasion by inhibiting MMP-9 expression via suppression of the PPAR-γ/NF-κB pathway in MCF-7 cells. Oncol Lett. 13:243–249. 2017. View Article : Google Scholar : PubMed/NCBI
36	Chung TW, Choi H, Lee JM, Ha SH, Kwak CH, Abekura F, Park JY, Chang YC, Ha KT, Cho SH, et al: Oldenlandia diffusa suppresses metastatic potential through inhibiting matrix metal-loproteinase-9 and intercellular adhesion molecule-1 expression via p38 and ERK1/2 MAPK pathways and induces apoptosis in human breast cancer MCF-7 cells. J Ethnopharmacol. 195:309–317. 2017. View Article : Google Scholar
37	Mohammadzadeh R, Saeid Harouyan M and Ale Taha SM: Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells. Tumour Biol. 39:10104283176959252017. View Article : Google Scholar : PubMed/NCBI
38	Kim JM, Noh EM, Kim HR, Kim MS, Song HK, Lee M, Yang SH, Lee GS, Moon HC, Kwon KB, et al: Suppression of TPA-induced cancer cell invasion by Peucedanum japonicum Thunb. extract through the inhibition of PKCα/NF-κB-dependent MMP-9 expression in MCF-7 cells. Int J Mol Med. 37:108–114. 2016. View Article : Google Scholar : PubMed/NCBI
39	Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M and Umezawa K: Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 11:1287–1293. 2005.PubMed/NCBI
40	Yu H, Guo C, Feng B, Liu J, Chen X, Wang D, Teng L, Li Y, Yin Q, Zhang Z, et al: Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-kappa B targeted treatment of metastatic breast cancer. Theranostics. 6:14–27. 2016. View Article : Google Scholar : PubMed/NCBI
41	Gutsche K, Randi EB, Blank V, Fink D, Wenger RH, Leo C and Scholz CC: Intermittent hypoxia confers pro-metastatic gene expression selectively through NF-κB in inflammatory breast cancer cells. Free Radic Biol Med. 101:129–142. 2016. View Article : Google Scholar : PubMed/NCBI
42	Senger DR, Wirth DF and Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 16:885–893. 1979. View Article : Google Scholar : PubMed/NCBI
43	Bao LH, Sakaguchi H, Fujimoto J and Tamaya T: Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci. 14:373–381. 2007. View Article : Google Scholar : PubMed/NCBI
44	Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
45	Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF and Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 145:610–623. 1994.PubMed/NCBI
46	Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S and Rittling SR: Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis. 20:77–84. 2003. View Article : Google Scholar : PubMed/NCBI
47	Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T and Shimada Y: An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res. 12:1308–1316. 2006. View Article : Google Scholar : PubMed/NCBI
48	Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, et al: Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med. 15:302017. View Article : Google Scholar : PubMed/NCBI
49	Xu YY, Zhang YY, Lu WF, Mi YJ and Chen YQ: Prognostic value of osteopontin expression in breast cancer: A meta-analysis. Mol Clin Oncol. 3:357–362. 2015. View Article : Google Scholar : PubMed/NCBI
50	Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC and Welch DR: Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem. 283:7438–7444. 2008. View Article : Google Scholar : PubMed/NCBI